
ATS 2026 showcased new pulmonary therapies, clinical trials, and cross-specialty collaboration to improve patient care.

ATS 2026 showcased new pulmonary therapies, clinical trials, and cross-specialty collaboration to improve patient care.

SUNRISE data showed tezepelumab improved asthma outcomes while reducing steroid dependence in severe asthma.

SUNRISE trial data showed tezepelumab reduced oral steroid use while maintaining asthma control in severe asthma.
